Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
:HBIO
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
0.02Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: -39.47%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive aspects such as sequential revenue growth, strategic product launches, and stable gross margins. However, these were balanced by significant challenges like year-over-year revenue decline, debt covenant non-compliance, and uncertainties around NIH funding. The sentiment reflects a cautious optimism, recognizing both opportunities and hurdles.Company Guidance
During the fourth quarter of fiscal year 2024, Harvard Bioscience reported revenue of $24.6 million, marking a 13% decline from the same period last year but a 12% sequential increase from the third quarter. The gross margin was $14 million, or 57% of revenue, while operating income broke even on a GAAP basis. Adjusted operating income was $2.5 million, accounting for 10% of revenue, and adjusted EBITDA was $3 million, representing 12% of revenue. The Americas saw a 3% sequential revenue growth but an 11% year-over-year decline. Europe experienced a 28% sequential increase, albeit a 7% year-over-year decrease, while the Asia Pacific region showed an 8% sequential increase but a 24% decline compared to the previous year. The company's financial outlook for the first quarter of 2025 anticipates revenues in the range of $19 million to $21 million and gross margins between 56% to 58%. They are working on refinancing their debt by June 30, 2025, due to non-compliance with the consolidated net leverage ratio covenant.Sequential Revenue Growth
Revenue in the fourth quarter was $24.6 million, showing a sequential increase of 12% from the third quarter.
Gross Margin Stability
Gross margin for the fourth quarter was 57%, close to the target of 60%, demonstrating effective cost management despite lower revenue.
Positive Book-to-Bill Ratio
The company reported a positive book-to-bill ratio, indicating a healthy demand pipeline.
Successful Product Launches
New products like the SoHo telemetry devices and VivaMARS neurobehavioral monitoring system are seeing strong demand, with early adopters including major institutions like Labcorp.
Strategic Partnerships
The company is working with large pharma companies for bioproduction applications, showcasing growth opportunities in electroporation and bioproduction.
Expansion of Distribution Agreements
Extended distribution agreements with large distributors like Fisher and VWR to include North America, increasing product reach.
---
HBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $0.76 | $0.68 | -10.53% |
| Nov 07, 2024 | $2.82 | $2.39 | -15.25% |
| Aug 08, 2024 | $2.79 | $3.12 | +11.83% |
| May 07, 2024 | $3.92 | $3.75 | -4.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Harvard Bioscience (HBIO) report earnings?
Harvard Bioscience (HBIO) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Harvard Bioscience (HBIO) earnings time?
Harvard Bioscience (HBIO) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HBIO EPS forecast?
HBIO EPS forecast for the fiscal quarter 2025 (Q1) is -0.04.
---